← Leaderboards
Brigitte Widemann
Clinical Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsClinical TrialsTumorChildEnrollmentPathogenesisMedullary Thyroid CarcinomaRefractoryEffective TherapyCollaborationsAdultNatural HistoryNeurofibromatosis 1FundingBaseDrug DevelopmentYoung AdultBiologyResearch PersonnelMedicalProgramsChildhoodSolid NeoplasmNew Agents
Grant awards (46)
Therapies for patients with rare tumors and genetic tumor predisposition$2,831,748
ZIA · FY2025 · CA · contact PI
MyPART: My Pediatric and Adult Rare Tumor Network - Cures$827,438
ZIA · FY2025 · CA · contact PI
MyPART: My Pediatric and Adult Rare Tumor Network - Cures$6,254,428
ZIA · FY2024 · CA · contact PI
Therapies for patients with rare tumors and genetic tumor predisposition$1,884,219
ZIA · FY2024 · CA · contact PI
MyPART: My Pediatric and Adult Rare Tumor Network - Cures$5,431,446
ZIA · FY2023 · CA · contact PI
Therapies for patients with rare tumors and genetic tumor predisposition$1,850,797
ZIA · FY2023 · CA · contact PI
Therapies for patients with rare tumors and genetic tumor predisposition$1,897,099
ZIA · FY2022 · CA · contact PI
MyPART: My Pediatric and Adult Rare Tumor Network - Cures$697,054
ZIA · FY2022 · CA · contact PI
MyPART: My Pediatric and Adult Rare Tumor Network - Cures$21,856,208
ZIA · FY2021 · CA · contact PI
Therapies for patients with rare tumors and genetic tumor predisposition$2,384,333
ZIA · FY2021 · CA · contact PI
MyPART: My Pediatric and Adult Rare Tumor Network - Cures$4,147,128
ZIA · FY2020 · CA · contact PI
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes$1,468,055
ZIA · FY2020 · CA · contact PI
Research and Development of Effective Therapies for Patients with Rare Tumors$629,166
ZIA · FY2020 · CA · contact PI
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes$1,507,659
ZIA · FY2019 · CA · contact PI
Research and Development of Effective Therapies for Patients with Rare Tumors$646,140
ZIA · FY2019 · CA · contact PI
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes$1,367,242
ZIA · FY2018 · CA · contact PI
Research and Development of Effective Therapies for Patients with Rare Tumors$911,495
ZIA · FY2018 · CA · contact PI
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes$1,001,699
ZIA · FY2017 · CA · contact PI
Clinical Development of Novel Drugs for Children with Refractory Cancers$667,799
ZIA · FY2017 · CA · contact PI
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes$1,005,422
ZIA · FY2016 · CA · contact PI
Clinical Development of Novel Drugs for Children with Refractory Cancers$670,281
ZIA · FY2016 · CA · contact PI
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes$1,005,177
ZIA · FY2015 · CA · contact PI
Clinical Development of Novel Drugs for Children with Refractory Cancers$670,118
ZIA · FY2015 · CA · contact PI
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes$1,038,724
ZIA · FY2014 · CA · contact PI
Clinical Development of Novel Drugs for Children with Refractory Cancers$692,483
ZIA · FY2014 · CA · contact PI
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes$1,011,508
ZIA · FY2013 · CA · contact PI
Clinical Development of Novel Drugs for Children with Refractory Cancers$674,339
ZIA · FY2013 · CA · contact PI
Development of Therapies for Neurofibromatosis Type 1 Related Tumors and other G$1,354,536
ZIA · FY2012 · CA · contact PI
Clinical Development of Novel Drugs for Children with Refractory Cancers$903,024
ZIA · FY2012 · CA · contact PI
Development of Therapies for Neurofibromatosis Type 1 Related Tumors and other G$1,320,573
ZIA · FY2011 · CA · contact PI
Clinical Development of Novel Drugs for Children with Refractory Cancers$880,382
ZIA · FY2011 · CA · contact PI
Development of Therapies for Neurofibromatosis Type 1 Related Tumors and other G$1,121,943
ZIA · FY2010 · CA · contact PI
Clinical Development of Novel Drugs for Children with Refractory Cancers$747,962
ZIA · FY2010 · CA · contact PI
Development of Therapies for Neurofibromatosis Type 1 Related Tumors and other G$569,285
ZIA · FY2009 · CA · contact PI
Clinical Development of Novel Drugs for Children with Refractory Cancers$243,979
ZIA · FY2009 · CA · contact PI
Development of Therapies for Neurofibromatosis Type 1 Related Tumors and other G$569,726
Z01 · FY2008 · CA · contact PI
Clinical Development of Novel Drugs for Children with Refractory Cancers$142,432
Z01 · FY2008 · CA · contact PI
Clinical Development of Therapies for Neurofibromatosis Type 1-Related Tumors$848,196
Z01 · FY2007 · CA · contact PI
Clinical Development of Novel Drugs for Children with Refractory Cancers$330,554
Z01 · FY2007 · CA · contact PI
Clinical Development of Novel Drugs for Children with Ca$0
Z01 · FY2006 · SC · contact PI
Clinical Development of Novel Drugs for Children with Ca$0
Z01 · FY2005 · SC
Clinical development of drugs for children with cancer &$0
Z01 · FY2004 · SC
Clinical development of novel drugs for children with ca$0
Z01 · FY2003 · SC
Clinical development of novel drugs for children with ca$0
Z01 · FY2002 · SC
Novel Drugs for Children With Cancer /Neurofibromatosis$0
Z01 · FY2001 · SC
NOVEL DRUGS FOR CHILDREN WITH CANCER &NEUROFIBROMATOSIS$0
Z01 · FY2000 · SC